This page contains a Flash digital edition of a book.
STEMCELL Technologies and Regenerative Medicine member news.


In keeping with its goal of becoming a leading provider of reagents to the regenerative medicine industry, STEMCELL Technologies continues to release new products which satisfy the unique needs of this growing area of research.


STEMCELL Technologies has expanded its human pluripotent stem cell (hPSC) product line with the addition of three new products.


StemAdhere™ Defined Matrix for hPSCs, is a defined, humanized matrix that supports long-term culture of hPSCs. It serves as an alternative to the commonly used Matrigel™


and may be used in combination with mTeSR™1 or TeSR™2 media for a completely defined, feeder-independent system.


STEMdiff™ APEL™ Medium is a defined, serum-free and animal component-free medium specifically developed to support hPSCs differentiation along ectoderm, mesoderm and endoderm lineages. It is a versatile, growth factor-free, basal medium that is to be supplemented with specific lineage-inducing factors.


STEMdiff™ Neural Induction Medium is a defined, serum-free medium for the differentiation of hPSCs to neural progenitor cells. It forms neural rosettes when used in conjunction


with AggreWell™ 800 plates which ensure uniformly-sized neural aggregate formation. Neural rosettes can then be selected and isolated using enzyme-free STEMdiff™ Neural Rosette Selection Reagent. Together this is a complete and highly efficient system to obtain up to 100% single neural progenitor cells within 12 days.


Further, mTeSR™1 and TeSR™2 media are the world recognized global standard for feeder-free maintenance of hPSCs. Together with the new products, STEMCELL Technologies offers the most complete and defined system for maintenance, expansion and differentiation of hPSCs. For more information, please visit www.stemcell.com


Spheritech Expand Operations


SpheriCellTM


macroporous biodegradable scaffold


Spheritech have recently moved to larger premises allowing an increase in staff levels to accommodate a growing demand for the company’s novel scaffolds and polymers. Spheritech hold a broad portfolio of IP covering a range of biocompatible and biodegradable polymers used in preparation of scaffolds for regenerative medicines and microspheres for cell culture and separation.


The technology used to generate optimum pore size and interconnectivity is covered by the first patent filed by Spheritech in 2009. More recently the company filed a patent on a novel biodegradable polymer which breaks down to yield naturally occurring amino acids. The primary building block of the polymer is already produced on a multi-ton scale by bacterial fermentation so ultimately the macroporous scaffolds and microspheres produced from this new biomaterial will have the additional advantage of being relatively inexpensive. These combined technologies allow Spheritech to cast a three dimensional biodegradable macroporous scaffold into virtually any shape. The level and


10 www.regener8.ac.uk


type of cross-linker used in the new polymers dictate the mechanical properties including rate of degradation strength and elasticity.


The microspheres produced by Spheritech for cell culture and separation of cells have the advantage of buoyancy which improves mixing in traditional bioreactors, shakers or stirred tanks. These buoyant microspheres are also available in paramagnetic form adding a third dimension to the flexibility of their handling properties.


For further information visit www.spheritech.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36